All Top 25 Pharmaceutical Companies Now Using Spotfire Software for Technical Decision Support.

Business/Technology Editors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2000

Leading Firms Using Spotfire Products Across Multiple Disciplines

to Access, Analyze and Publish Discovery Information

Spotfire(R), Inc., a leading provider of technical and scientific decision support software, today announced that among its 200 customers are all of the top 25 pharmaceutical firms in the U.S. and Europe, measured in terms of revenue. Pharmaceutical customers are adopting Spotfire's software to make better decisions across a wide range of scientific disciplines.

In addition, Spotfire has aligned with many of the industry's key data content and instrumentation providers through the Spotfire Network Partnership Program. This has enabled Spotfire to integrate its products with many types of discovery data sources. Tight integration allows scientists and executives to access data from different stages of the drug discovery process, examine relationships and trends that would otherwise be difficult to identify, and then publish and share their findings with colleagues.

Spotfire solutions are ideally suited for supporting R&D activities within the life and material sciences. For instance, at life sciences companies where scientists must make decisions each day based on analyses of enormous amounts of chemical-compound, gene-expression, toxicology or clinical-trials data, Spotfire can be used to aid in the decision-making process. Material sciences firms also use Spotfire offerings to analyze formulation, catalysis and manufacturing process data.

"Spotfire has achieved rapid acceptance among large pharmaceutical firms, as well as their research partners in biotechnology, because of the need to analyze the huge amounts of technical data flooding the discovery process," said Dr. Christopher Ahlberg, Founder and CEO of Spotfire, Inc. "No other solution gives scientists and managers the ability to analyze discovery data as efficiently and effectively. Giving researchers the tools they need to identify leads faster and make better, more informed decisions enables pharmaceutical companies to achieve higher, faster returns on their investments."

Spotfire software is currently being used to support activities as diverse as:

--Rapidly assessing the quality of high-throughput screening leads to narrow the scope of research to include only the most promising drug candidates,

--Running bioavailability studies to better understand the effectiveness of potential drugs against specific indications,

--Evaluating pharmacogenomics data to analyze varying levels of efficacy of certain therapeutics in different individuals,

--Profiling huge amounts of genetic and proteomic analysis data to center research on potential new drug candidates,

--Comparing chemical compound libraries with patent and intellectual property data to identify unprotected market opportunities,

--Analyzing clinical trials data to assess the efficacy of promising new treatments,

--Comparing relationships between chemical structure and compound activity to focus research on chemicals with similar characteristics.

Spotfire, Inc.

Spotfire, Inc. is a premier supplier of technical and scientific decision support solutions to the life and material sciences industries. Spotfire software enables scientists and management to collaborate via the Web and empowers them to make sound decisions about the direction of future research. Spotfire supports high-performance discovery at the top 25 pharmaceutical companies and 40 major biotech and ag bio firms, among its 200 customers worldwide. The company maintains European headquarters in Goteborg, Sweden, and U.S. headquarters in Cambridge, Mass.

Spotfire is a registered trademark of Spotfire, Inc. All other names or marks may be registered trademarks or trademarks of their respective owners and are hereby acknowledged.